AttendMe Owl Logo
AttendMe
Evidence Evolution
Vascular SurgeryVascular Surgery

How This Evidence Evolved

AAA Repair: Open vs Endovascular

From Open Surgical Repair to EVAR and the Long-Term Equipoise Debate

34.1

Timeline

Signal

Early observations and pilot data that first suggested a new direction

The early endovascular aneurysm repair report described animal experiments and initial treatment in five patients with serious comorbidities. A stent-anchored Dacron graft was placed through retrograde cannulation of the common femoral artery under local or regional anesthesia. The graft excluded the aneurysm from circulation while preserving flow through its lumen. The authors called for further development and clinical trials before widespread use.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Randomized trials compared endovascular aneurysm repair (EVAR) with open repair. The early EVAR-1 report randomized 1082 patients. Thirty-day mortality was 1.7% with EVAR versus 4.7% with open repair (OR 0.35, 95% CI 0.16-0.77; P=.009). DREAM analyzed 345 patients; operative mortality was 1.2% with EVAR versus 4.6% with open repair, with an open-to-EVAR risk ratio of 3.9 (95% CI 0.9-32.9). OVER randomized 881 veterans. Perioperative mortality was 0.5% versus 3.0% (P=.004), while mortality at 2 years did not differ significantly (7.0% versus 9.8%; P=.13).
Extension

Follow-up studies, subgroup analyses, and real-world validation

Long-term trials gave different results. EVAR-1 follow-up, published in 2016, included 1252 patients. Beyond 8 years, mortality was higher with EVAR: adjusted HR 1.25 (95% CI 1.00-1.56) for all-cause death and 5.82 (1.64-20.65) for aneurysm-related death. Secondary sac rupture accounted for much of the late aneurysm mortality. OVER followed 881 patients for up to 14 years and found similar overall survival (HR 0.96, 95% CI 0.82-1.13). In EVAR-2, patients unfit for open repair had lower aneurysm mortality with EVAR but no reduction in total mortality versus no repair (HR 0.99, 95% CI 0.78-1.27; P=.97).
Now

Current standard of care and ongoing research directions

Long-term results differ across randomized studies. In EVAR-1, mortality beyond 8 years was higher with EVAR: all-cause adjusted HR 1.25 (95% CI 1.00–1.56) and aneurysm-related HR 5.82 (1.64–20.65). OVER found similar overall survival through up to 14 years (HR 0.96, 95% CI 0.82–1.13). Among patients physically ineligible for open repair, EVAR-2 found lower aneurysm mortality without a total-mortality benefit over no repair (HR 0.99, 95% CI 0.78–1.27). These populations and follow-up periods matter when discussing early benefit and late risk. How should device durability, surveillance burden and patient-specific risk inform comparative research?

Landmark Trials in This Story

Parodi 19911991Landmark

Transfemoral intraluminal graft implantation for abdominal aortic aneurysms

Technical success of endovascular graft deployment

Annals of vascular surgeryCase seriesN=5
EVAR-1 early outcomes2004

Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial.

30-day operative mortality: EVAR 1.7% vs open 4.7% (OR 0.35, 95% CI 0.16-0.77; P=.009)

LancetRandomized comparison of EVAR with open repairN=1,082
DREAM2004

A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms.

Operative mortality at 30 days: open 4.6% vs EVAR 1.2% (RR 3.9, 95% CI 0.9–32.9).

The New England journal of medicineRandomized trial of open versus endovascular repair in patients suitable for both approaches.N=345
OVER early outcomes2009

Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial.

Perioperative mortality (30 days or inpatient): EVAR 0.5% vs open 3.0% (P=.004); mortality at 2 years 7.0% vs 9.8% (P=.13)

JAMARandomized multicentre trial in veteransN=881
DREAM primary report2004

A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms.

Operative mortality at 30 days: open 4.6% vs EVAR 1.2% (RR 3.9, 95% CI 0.9-32.9)

N Engl J MedMulticentre randomized comparison of open and endovascular repairN=345
EVAR-1 long-term follow-up2016

Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial.

Mortality beyond 8 years, EVAR vs open: all-cause adjusted HR 1.25 (95% CI 1.00-1.56; P=.048); aneurysm-related HR 5.82 (1.64-20.65; P=.0064)

LancetLong-term follow-up of randomized EVAR-1 trialN=1,252
OVER Long-term2019

Open versus Endovascular Repair of Abdominal Aortic Aneurysm.

All-cause mortality through up to 14 years: EVAR 68.0% vs open 70.0% (HR 0.96, 95% CI 0.82–1.13).

The New England journal of medicineRandomized trial; follow-up of patients assigned to endovascular or open abdominal aortic aneurysm repair.N=881
OVER long-term follow-up2019

Open versus Endovascular Repair of Abdominal Aortic Aneurysm.

All-cause mortality through up to 14 years: EVAR 68.0% vs open 70.0% (HR 0.96, 95% CI 0.82-1.13)

N Engl J MedRandomized trial follow-up for up to 14 yearsN=881
EVAR-22010

Endovascular repair of aortic aneurysm in patients physically ineligible for open repair.

Total mortality during follow-up through 2009: EVAR vs no repair adjusted HR 0.99 (95% CI 0.78-1.27; P=.97); aneurysm mortality HR 0.53 (0.32-0.89; P=.02)

N Engl J MedRandomized trial in patients physically ineligible for open repairN=404
Hostile-neck EVAR meta-analysis2013

A meta-analysis of outcomes of endovascular abdominal aortic aneurysm repair in patients with hostile and friendly neck anatomy.

Type I endoleak within 1 year: hostile vs favorable neck anatomy OR 4.563 (95% CI 1.430-14.558)

J Vasc SurgSystematic review and meta-analysis of seven observational studiesN=1,559
AAA volume-outcome meta-analysis2007

Meta-analysis and systematic review of the relationship between volume and outcome in abdominal aortic aneurysm surgery.

Mortality at higher-volume hospitals: elective repair OR 0.66 (95% CI 0.65-0.67), threshold 43 per year; ruptured repair OR 0.78 (0.73-0.82), threshold 15 per year

Br J SurgSystematic review and meta-analysis of elective and ruptured AAA surgery

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Does EVAR provide a long-term survival advantage over open AAA repair?+
EVAR has lower early mortality in several trials, but long-term results differ. In EVAR-1, mortality beyond 8 years was higher after EVAR (all-cause HR 1.25, 95% CI 1.00-1.56; aneurysm-related HR 5.82, 95% CI 1.64-20.65). Secondary aneurysm sac rupture contributed to late deaths. OVER found similar overall survival through up to 14 years (HR 0.96, 95% CI 0.82-1.13).
What is the reintervention rate after EVAR versus open repair?+
The early EVAR-1 report found more secondary interventions after EVAR than open repair (9.8% versus 5.8%; P=.02). Long-term follow-up linked late aneurysm mortality to secondary sac rupture and called for lifelong surveillance with reintervention when needed.
What anatomic criteria determine EVAR suitability?+
A meta-analysis of seven observational studies found higher type I endoleak risk within 1 year with hostile versus favorable neck anatomy (OR 4.563, 95% CI 1.430-14.558). The authors found insufficient high-level evidence for or against standard EVAR in hostile anatomy.
Should AAA repair be centralized to high-volume centers?+
A volume-outcome meta-analysis associated higher hospital volume with lower mortality in elective AAA repair (OR 0.66, 95% CI 0.65-0.67, at a threshold of 43 operations per year) and ruptured AAA repair (OR 0.78, 95% CI 0.73-0.82, at 15 operations per year).

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026